welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
study id #: NCT01540604
condition: Duchenne Muscular Dystrophy , Becker Muscular Dystrophy
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
mechanism of action: Non-steroidal agent to decrease inflammation
last updated: November 22, 2018
phase of development: Phase 2
Documented diagnosis of dystrophinopathy
Severe functional impairment
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy (DMD) is a g...
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular DystrophyThis study, supported by Charley's Fund,...
Archived drug prevents Duchenne muscular dystrophy muscle loss in miceA drug that showed promise in clinical t...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, ran...Background: Duchenne muscular dystrophy...